UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Mechanisms of Therapeutic Antitumor Monoclonal Antibodies

Cancer research (Chicago, Ill.), 2021-09, Vol.81 (18), p.4641-4651

2021

Volltextzugriff (PDF)

ASO Visual Abstract: Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer—Comparison of Approaches

Annals of surgical oncology, 2023-10, Vol.30 (10), p.6151-6151

2023

Volltextzugriff (PDF)

Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database

Annals of surgical oncology, 2018-08, Vol.25 (8), p.2249-2260

2018

Volltextzugriff (PDF)

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading

Current treatment options in oncology, 2019-04, Vol.20 (4), p.35-35, Article 35

2019

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer: Comparison of Approaches

Annals of surgical oncology, 2023-10, Vol.30 (10), p.6141-6150

2023

Volltextzugriff (PDF)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

EMBO molecular medicine, 2023-10, Vol.15 (10), p.e17367-e17367

2023

Volltextzugriff (PDF)

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Clinical cancer research, 2007-05, Vol.13 (9), p.2643-2650

2007

Volltextzugriff (PDF)

First-line treatment of metastatic melanoma: role of nivolumab

ImmunoTargets and therapy, 2017-01, Vol.6, p.1-10

2017

Volltextzugriff (PDF)

Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity

Clinical cancer research, 2005-05, Vol.11 (9), p.3514-3522

2005

Volltextzugriff (PDF)

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

NPJ breast cancer, 2022-12, Vol.8 (1), p.134-134, Article 134

2022

Volltextzugriff (PDF)

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Clinical cancer research, 2008-10, Vol.14 (20), p.6478-6486

2008

Volltextzugriff (PDF)

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium

Journal of Cancer, 2019-01, Vol.10 (15), p.3344-3351

2019

Volltextzugriff (PDF)

Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer

Current treatment options in oncology, 2021-03, Vol.22 (5), p.38-38, Article 38

2021

Volltextzugriff (PDF)

Mechanisms of therapeutic anti-tumor monoclonal antibodies

Cancer research (Chicago, Ill.), 2021-06, Vol.81 (18), p.4641-4651

2021

Volltextzugriff (PDF)

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)

Annals of surgery, 2018-10, Vol.268 (4), p.591-601

2018

Volltextzugriff (PDF)

Advancing TNBC care in the community oncology practice: Insights from a quality improvement initiative

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18762-e18762

2023

Volltextzugriff (PDF)

Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

Breast cancer research and treatment, 2023, Vol.197 (2), p.369-376

2023

Volltextzugriff (PDF)

Clinical trials of self-replicating RNA-based cancer vaccines

Cancer gene therapy, 2023-06, Vol.30 (6), p.803-811

2023

Volltextzugriff (PDF)

Abstract PS16-05: Identification of pathogenic RET alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS16-05-PS16-05

2021

Volltextzugriff (PDF)

Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-33-PS13-33

2021

Volltextzugriff (PDF)

Abstract PS16-06: Identification of pathogenic FGFR1, FGFR2, and FGFR3 alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS16-06-PS16-06

2021

Volltextzugriff (PDF)

A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates

Annals of surgery, 2022-04, Vol.275 (4), p.784

2022

Volltextzugriff (PDF)

Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1107-1107

2023

Volltextzugriff (PDF)

RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence

Cell death and differentiation, 2020-07, Vol.27 (7), p.2234-2247

2020

Volltextzugriff (PDF)

Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1028-1028

2021

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mechanisms of Therapeutic Antitumor Monoclonal Antibodies

ASO Visual Abstract: Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer—Comparison of Approaches

Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading

Neoadjuvant Chemotherapy and Endocrine Therapy for Older Patients with Estrogen Receptor Positive Breast Cancer: Comparison of Approaches

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

First-line treatment of metastatic melanoma: role of nivolumab

Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium

Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer

Mechanisms of therapeutic anti-tumor monoclonal antibodies

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB)

Advancing TNBC care in the community oncology practice: Insights from a quality improvement initiative

Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

Clinical trials of self-replicating RNA-based cancer vaccines

Abstract PS16-05: Identification of pathogenic RET alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer

Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan

Abstract PS16-06: Identification of pathogenic FGFR1, FGFR2, and FGFR3 alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer

A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates

Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC)

RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence

Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer

Suchergebnisse filtern